Update on laboratory practice for the diagnosis of lupus anticoagulant and the antiphospholipid syndrome
Antiphospholipid syndrome (APS) is defined as an autoimmune and prothrombotic disorder in patients with the persistent presence of antiphospholipid antibodies (aPLs). In the classification criteria, aPL expresses lupus anticoagulant (LA) activity, which is detected by prolongation of coagulation ass...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Open Exploration Publishing Inc.
2023-10-01
|
| Series: | Exploration of Immunology |
| Subjects: | |
| Online Access: | https://www.explorationpub.com/Journals/ei/Article/1003110 |
| _version_ | 1797660705779875840 |
|---|---|
| author | Osamu Kumano Marie Peyrafitte Jean Amiral |
| author_facet | Osamu Kumano Marie Peyrafitte Jean Amiral |
| author_sort | Osamu Kumano |
| collection | DOAJ |
| description | Antiphospholipid syndrome (APS) is defined as an autoimmune and prothrombotic disorder in patients with the persistent presence of antiphospholipid antibodies (aPLs). In the classification criteria, aPL expresses lupus anticoagulant (LA) activity, which is detected by prolongation of coagulation assays. The LA detection algorithm is a sequential flow including screening tests, mixing tests, and confirmatory tests to differentiate between LA-positive and other anticoagulant abnormalities. Two types of assays are used, like dilute Russell’s viper venom time (dRVVT) and activated partial thromboplastin time (APTT) because no single test is sensitive to all LAs. The anticoagulant drugs prescribed for the prevention and treatment of thrombosis disorders can interfere with the assays, and it is important to know the effects of these drugs in the assays. Especially, new generation anticoagulant drugs, called direct oral anticoagulants (DOACs), affect the results. In this review, the following points are discussed: i) LA detection flow and data interpretation, ii) the principles of coagulation assays proposed and their characteristics, and iii) the effects of anticoagulant drugs in LA detection. |
| first_indexed | 2024-03-11T18:33:49Z |
| format | Article |
| id | doaj.art-467ad1c463c94856aeed6cf989a3dd68 |
| institution | Directory Open Access Journal |
| issn | 2768-6655 |
| language | English |
| last_indexed | 2024-03-11T18:33:49Z |
| publishDate | 2023-10-01 |
| publisher | Open Exploration Publishing Inc. |
| record_format | Article |
| series | Exploration of Immunology |
| spelling | doaj.art-467ad1c463c94856aeed6cf989a3dd682023-10-13T06:04:45ZengOpen Exploration Publishing Inc.Exploration of Immunology2768-66552023-10-013541643210.37349/ei.2023.00110Update on laboratory practice for the diagnosis of lupus anticoagulant and the antiphospholipid syndromeOsamu Kumano0https://orcid.org/0000-0001-6650-0567Marie Peyrafitte1Jean Amiral2https://orcid.org/0000-0002-0680-9172HYPHEN BioMed, 155 Rue d’Eragny, 95000 Neuville sur Oise, France; Health and Medical Research Institute, National Institute of Advanced Industrial Science and Technology (AIST), 2217-14, Hayashi-cho, Takamatsu, Kagawa 761-0395, JapanHYPHEN BioMed, 155 Rue d’Eragny, 95000 Neuville sur Oise, FranceSH-Consulting, 95130 Franconville, FranceAntiphospholipid syndrome (APS) is defined as an autoimmune and prothrombotic disorder in patients with the persistent presence of antiphospholipid antibodies (aPLs). In the classification criteria, aPL expresses lupus anticoagulant (LA) activity, which is detected by prolongation of coagulation assays. The LA detection algorithm is a sequential flow including screening tests, mixing tests, and confirmatory tests to differentiate between LA-positive and other anticoagulant abnormalities. Two types of assays are used, like dilute Russell’s viper venom time (dRVVT) and activated partial thromboplastin time (APTT) because no single test is sensitive to all LAs. The anticoagulant drugs prescribed for the prevention and treatment of thrombosis disorders can interfere with the assays, and it is important to know the effects of these drugs in the assays. Especially, new generation anticoagulant drugs, called direct oral anticoagulants (DOACs), affect the results. In this review, the following points are discussed: i) LA detection flow and data interpretation, ii) the principles of coagulation assays proposed and their characteristics, and iii) the effects of anticoagulant drugs in LA detection.https://www.explorationpub.com/Journals/ei/Article/1003110lupus anticoagulantthrombosisantiphospholipid syndromeantiphospholipid antibodiesactivated partial thromboplastin timedilute russell’s viper venom time |
| spellingShingle | Osamu Kumano Marie Peyrafitte Jean Amiral Update on laboratory practice for the diagnosis of lupus anticoagulant and the antiphospholipid syndrome Exploration of Immunology lupus anticoagulant thrombosis antiphospholipid syndrome antiphospholipid antibodies activated partial thromboplastin time dilute russell’s viper venom time |
| title | Update on laboratory practice for the diagnosis of lupus anticoagulant and the antiphospholipid syndrome |
| title_full | Update on laboratory practice for the diagnosis of lupus anticoagulant and the antiphospholipid syndrome |
| title_fullStr | Update on laboratory practice for the diagnosis of lupus anticoagulant and the antiphospholipid syndrome |
| title_full_unstemmed | Update on laboratory practice for the diagnosis of lupus anticoagulant and the antiphospholipid syndrome |
| title_short | Update on laboratory practice for the diagnosis of lupus anticoagulant and the antiphospholipid syndrome |
| title_sort | update on laboratory practice for the diagnosis of lupus anticoagulant and the antiphospholipid syndrome |
| topic | lupus anticoagulant thrombosis antiphospholipid syndrome antiphospholipid antibodies activated partial thromboplastin time dilute russell’s viper venom time |
| url | https://www.explorationpub.com/Journals/ei/Article/1003110 |
| work_keys_str_mv | AT osamukumano updateonlaboratorypracticeforthediagnosisoflupusanticoagulantandtheantiphospholipidsyndrome AT mariepeyrafitte updateonlaboratorypracticeforthediagnosisoflupusanticoagulantandtheantiphospholipidsyndrome AT jeanamiral updateonlaboratorypracticeforthediagnosisoflupusanticoagulantandtheantiphospholipidsyndrome |